Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results

17 Feb 2022

Abstract excerpt

Not available.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood groups and transfusion
Share to Erythrocyte Function and Pathophysiology
Share to Platelet Disorders and Treatments

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 35172561
DOI: 10.3324/haematol.2021.279812

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up resultsPMID 35172561Read ↗

Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part BSemantic proximity Read ↗

Complement C5 inhibition in patients with COVID-19 - a promising target?Semantic proximity Read ↗

Complement Inhibition with the C5 Blocker LFG316 in Severe COVID-19Semantic proximity Read ↗

Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapySemantic proximity Read ↗

Narsoplimab Results in Excellent Survival in Adults and Children With Hematopoietic Cell Transplant Associated Thrombotic Microangiopathy ( TA ‐ TMA )Semantic proximity Read ↗

Compstatins: the dawn of clinical C3-targeted complement inhibitionSemantic proximity Read ↗

Chronic ataxic neuropathy with cold agglutinins: atypical phenotype and response to anti-CD20 antibodies.Semantic proximity Read ↗

The impact of eculizumab on routine complement assaysSemantic proximity Read ↗

Real-World Effectiveness and Safety of Avacopan in ANCA-Associated Vasculitis: A Systematic Literature Review and Meta-analysisSemantic proximity Read ↗

First‐in‐human study with SAR445088: A novel selective classical complement pathway inhibitorSemantic proximity Read ↗

Use of the complement inhibitor Coversin to treat HSCT-associated TMASemantic proximity Read ↗

Immunoglobulin heavy and light chain gene features are correlated with primary cold agglutinin disease onset and activitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.